Barclays Initiates Coverage On Madrigal Pharmaceuticals with Overweight Rating, Announces Price Target of $964
Benzinga Newsdesk 9 months ago
NewsPrice TargetInitiationAnalyst Ratings
Barclays analyst Eliana Merle initiates coverage on Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Overweight rating and announces Price Target of $964.
Barclays analyst Eliana Merle initiates coverage on Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Overweight rating and announces Price Target of $964.